A new pricing platform for a new generation of therapies
Pharma and biotech pipelines are full of precision and targeted medicines. But traditional payment and rebate processes are designed for one price or rebate per product, not per use or indication as new therapies require. For combination therapies, companies cannot coordinate pricing and agree how to share value. There’s a need for platform to facilitate flexible pricing per indication and enable contingent commitments for combinations.
We have adapted tools from the finance industry to the existing market access process in Europe to solve this problem. Collaborating with pharma affiliates, national payers, industry associations, data providers and financial institutions, we are launching the Contingent Commitment Exchange to solve market access for a new generation of innovative therapies.